Abstract
Overexpression of HER-2/neu in human breast carcinomas correlates with poor prognosis, although its strength as a prognostic indicator varies widely in different reports. Variability may be due to active signalling by HER-2/neu in a subset of the tumours in which it is overexpressed. To study this hypothesis, we have developed an activation state-specific anti-HER-2/neu monoclonal antibody. In this report, we use this antibody to analyse the signalling status of HER-2/neu in a large series of invasive breast carcinomas. Overexpression of HER-2/neu was detected in 9% of 223 cases. Of the cases demonstrating overexpression, active signalling by HER-2/neu was detected in only 35%. The clinicopathological characteristics of these cases are described. This functional assay is predicted to improve the utility of HER-2/ neu as a prognostic indicator.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DiGiovanna, M., Carter, D., Flynn, S. et al. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 74, 802–806 (1996). https://doi.org/10.1038/bjc.1996.439
Issue Date:
DOI: https://doi.org/10.1038/bjc.1996.439
This article is cited by
-
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptinâ„¢) in HER2-overexpressing breast cancer cells
BMC Cancer (2007)
-
Extracting Functional Information From Tissues
Molecular Diagnosis (2001)
-
Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
Breast Cancer Research (2000)